Biliary tract cancers (BTC), including cholangiocarcinoma and gallbladder cancer, are poor-
prognosis and low-incidence cancers, although the incidence of intrahepatic …

Biliary tract cancers (cholangiocarcinomas and gallbladder cancers) are increasing in
incidence and have a poor prognosis. Most patients present with advanced disease, for …

Background Gemcitabine plus a platinum-based agent (eg, cisplatin or oxaliplatin) is the
standard of care for advanced biliary cancers. We investigated the addition of cetuximab to …

Cholangiocarcinomas are rare biliary tract tumors that are often challenging to diagnose and
treat. Cholangiocarcinomas are generally categorized as intrahepatic or extrahepatic …

Abstract Purpose of Review Cholangiocarcinoma is a rare biliary adenocarcinoma
associated with poor outcomes. Cholangiocarcinoma is subdivided into extrahepatic and …

Intrahepatic cholangiocarcinoma (ICC) is an aggressive malignancy with very poor
prognosis. Genome-wide, high-throughput technologies have made major advances in …

Biliary tract cancers (BTCs) are rare with poor prognosis. Due to the advent of genomic
sequencing, new data have emerged regarding the molecular makeup of this disease. To …

Intrahepatic cholangiocarcinoma (ICC) is the second most common primary hepatic
malignancy after hepatocellular carcinoma (HCC), accounting for 10% to 15% of primary …

BACKGROUND Biliary tract cancer (BTC) is a rare and lethal disease with few therapeutic
options. Preclinical data suggest that the epidermal growth factor receptor (EGFR) pathway …

Addition of cetuximab showed trend, but not significantly, to improve the therapeutic effects
of gemcitabine and oxaliplatin combination for advanced biliary tract cancer in current …